1. |
Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Intern J Surg, 2012, 10(1): 28-55.
|
2. |
Kay R. Statistical thinking for non-statisticians in drug regulation. New York: John Wiley, 2009.
|
3. |
King MT. A point of minimal important difference (MID): a critique of terminology and methods. Expert Rev Pharmacoecon Outcomes Res, 2011, 11(2): 171-184.
|
4. |
Guyatt G, Walter S, Norman G. Measuring change over time: assessing the usefulness of evaluative instruments. J Chronic Dis, 1987, 40(2): 171-178.
|
5. |
Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials, 1989, 10(4): 407-415.
|
6. |
Guyatt GH, Osoba D, Wu AW, et al. Methods to explain the clinical significance of health status measures. Mayo Clin Proc, 2002, 77(4): 371-383.
|
7. |
Norman GR, Sloan JA, Wyrwich KW. Interpretation of changes in health-related quality of life: the remarkable universality of half a standard deviation. Med Care, 2003, 41(5): 582-592.
|
8. |
Turner D, Schünemann HJ, Griffith LE, et al. The minimal detectable change cannot reliably replace the minimal important difference. J Clin Epidemiol, 2010, 63(1): 28-36.
|
9. |
de Vet HC, Terwee CB. The minimal detectable change should not replace the minimal important difference. J Clin Epidemiol, 2010, 63(7): 804-805.
|
10. |
Barrett B, Brown D, Mundt M, et al. Sufficiently important difference: expanding the framework of clinical significance. Med Decis Making, 2005, 25(3): 250-261.
|
11. |
Sloan JA, Cella D, Frost M, et al. Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms. Mayo Clin Proc, 2002, 77(4): 367-370.
|
12. |
Wyrwich KW, Bullinger M, Aaronson N, et al. Estimating clinically significant differences in quality of life outcomes. Qual Life Res, 2005, 14(2): 285-295.
|
13. |
Lidwine BM, Caroline BT, Donald LP, et al. COSMIN checklist manual, 2012. Available at: http://facksuedusa/sites/default/files/cosmin_checklist_manual_v9pdf.
|
14. |
de Vet HC, Beckerman H, Terwee CB, et al. Definition of clinical differences. J Rheumatol, 2006, 33(2): 434.
|
15. |
Beaton DE, Bombardier C, Katz JN, et al. Looking for important change/differences in studies of responsiveness. OMERACT MCID Working Group. Outcome Measures in Rheumatology. Minimal Clinically Important Difference. J Rheumatol, 2001, 28(2): 400-405.
|
16. |
de Vet HC, Terwee CB, Ostelo RW, et al. Minimal changes in health status questionnaires: Distinction between minimally detectable change and minimally important change. Health Qual Life Outcomes, 2006, 4: 54.
|
17. |
Beckerman H, Roebroeck ME, Lankhorst GJ, et al. Smallest real difference, a link between reproducibility and responsiveness. Qual Life Res, 2001, 10(7): 571-578.
|
18. |
Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum, 2001, 45(4): 384-391.
|
19. |
Revicki D, Hays RD, Cella D, et al. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol, 2008, 61(2): 102-109.
|
20. |
Osoba DK. Interpreting QOL in individuals and groups: meaningful differences. In: Assessing Quality of Life in Clinical Trials: Methods and Practice. Oxford: Oxford University Press, 2005.
|
21. |
Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol, 2002, 14(2): 109-114.
|
22. |
Witt S, Krauss E, Barbero MAN, et al. Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respir Res, 2019, 20(1): 47.
|
23. |
Gupta S, Chandra D, Sciurba F. Minimal or maximal clinically important difference: using death to define MCID. Am J Respir Crit Care Med, 2013, 187(12): 1391-1392.
|
24. |
Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med, 2013, 187(4): 382-386.
|
25. |
Polkey MI, Spruit MA, Wouters E, et al. Reply: minimal or maximal clinically important difference: using death to define MCID. Am J Respir Crit Care Med, 2013, 187(12): 1392.
|
26. |
万崇华, 禹玉兰, 谭健烽, 等. 生命质量研究导论. 北京: 科学出版社, 2016.
|
27. |
许传志, 陈莹. 基于量表得分的最小临床重要性差值(MCID)制定方法. 中国卫生统计, 2019, 36(3): 436-440.
|
28. |
王家良. 临床流行病学—临床科研设计, 测量与评价(第三版). 上海: 上海科学技术出版社, 2009.
|
29. |
Patrick DL, Gagnon DD, Zagari MJ, et al. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer, 2003, 39(3): 335-345.
|
30. |
McGlothlin AE, Lewis RJ. Minimal clinically important difference: defining what really matters to patients. JAMA, 2014, 312(13): 1342-1343.
|
31. |
Speer DC, Greenbaum PE. Five methods for computing significant individual client change and improvement rates: support for an individual growth curve approach. J Consult Clin Psychol, 1995, 63(6): 1044-1048.
|
32. |
Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol, 2003, 56(5): 395-407.
|
33. |
Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods, 2002, 7(2): 147-177.
|
34. |
Cohen J. Statistical power analysis for the behavioural sciences (2nd Edition). NJ: Lawrence Erlbaum Associates, 1988.
|
35. |
Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark Ⅱ. Pharmacoeconomics, 1999, 15(2): 141-155.
|
36. |
Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care, 1989, 27(3 Suppl): S178-189.
|
37. |
Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care, 1990, 28(7): 632-642.
|
38. |
方积乾. 生存质量: 测定方法及应用. 北京: 北京大学医学出版社, 2006.
|
39. |
Wyrwich KW, Nienaber NA, Tierney WM, et al. Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life. Med Care, 1999, 37(5): 469-478.
|
40. |
Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol, 1999, 52(9): 861-873.
|
41. |
Nolan CM, Delogu V, Maddocks M, et al. Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective study. Thorax, 2018, 73: 680-682.
|
42. |
Shikiar R, Harding G, Leahy M, et al. Minimal important difference (MID) of the dermatology life quality index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes, 2005, 3: 36.
|
43. |
Wells G, Beaton D, Shea B, et al. Minimal clinically important differences: review of methods. J Rheumatol, 2001, 28(2): 406-412.
|
44. |
Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol, 1991, 59(1): 12-19.
|
45. |
Beaton DE, Bombardier C, Katz JN, et al. A taxonomy for responsiveness. J Clin Epidemiol, 2001, 54(12): 1204-1217.
|
46. |
FDA. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims, 2009. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims.
|
47. |
van der Heijde D, Lassere M, Edmonds J, et al. Minimal clinically important difference in plain films in RA: group discussions, conclusions, and recommendations. OMERACT Imaging Task Force. J Rheumatol, 2001, 28(4): 914-917.
|
48. |
N B. Musculoskeletal clinical metrology. Lancaster: Kluwer Academic Publishers, 1993.
|
49. |
Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum, 1995, 38(6): 727-735.
|
50. |
Oliveira A, Machado A, Marques A. Minimal important and detectable differences of respiratory measures in outpatients with AECOPD. COPD, 2018, 15(5): 479-488.
|
51. |
Mahler DA, Ward J, Waterman LA, et al. Patient-reported dyspnea in COPD reliability and association with stage of disease. Chest, 2009, 136(6): 1473-1479.
|
52. |
Oliveira A, Lage S, Rodrigues J, et al. Reliability, validity and minimal detectable change of computerized respiratory sounds in patients with chronic obstructive pulmonary disease. Clin Respir J, 2018, 12(5): 1838-1848.
|
53. |
Kon SS, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: a prospective analysis. Lancet Respir Med, 2014, 2(3): 195-203.
|
54. |
Johnston BC, Ebrahim S, Carrasco-Labra A, et al. Minimally important difference estimates and methods: A protocol. BMJ Open, 2015, 5: e007953.
|